Novavax (Nasdaq:NVAX) announced that its protein-based NVX-CoV2373 COVID-19 vaccine could be the first of its type to be available in the U.S., assuming it wins backing from the FDA and CDC.
The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) have secured 3.2 million doses of Novavax’s COVID-19 vaccine.
There are currently two FDA-approved mRNA vaccines and an authorized adenovirus vector vaccine.
The protein-based Novavax vaccine is built using a more traditional technique than rivals and is adjuvanted to enhance the immune response. Hepatitis B and shingles vaccines are also protein-based and adjuvanted.
The vaccine includes a small amount of the SARS-CoV-2 spike protein.
In June, an FDA advisory committee recommended authorization of the Novavax vaccine.
Typically, FDA grants authorization soon after hearing from its advisors but has not yet authorized the Novavax vaccine.